07:35 AM EDT, 06/25/2025 (MT Newswires) -- Gilead Sciences ( GILD ) and Kymera Therapeutics ( KYMR ) said Wednesday they have signed an exclusive option and license agreement to develop and commercialize a new molecular glue degrader program targeting cyclin-dependent kinase 2, a key driver of tumor growth.

Under the deal, Kymera could receive up to $750 million, including up to $85 million in upfront and potential option payments. The company may also receive tiered royalties on future sales.

Kymera will lead research, while Gilead will assume global development and commercialization rights if it exercises its licensing option, the companies said.

The deal with Kymera is expected to reduce Gilead's 2025 per-share earnings by about $0.02 to $0.03.